SMAD7
SMAD7 (SMAD family member 7, also known as MADH7 or MADH8) is a member of the dwarfin/SMAD family that antagonises signalling by the TGF-beta type 1 receptor superfamily. It acts at the receptor level, restraining TGF-beta and activin signalling. Browse Assay Genie's current range of SMAD7 research reagents below, or read on for the biology behind the target.
SMAD7 is an antagonist of signalling by members of the TGF-beta (transforming growth factor) type 1 receptor superfamily. It has been shown to inhibit TGF-beta and activin signalling by associating with their receptors, which prevents SMAD2 from gaining access. It also works as an adapter, recruiting the E3 ubiquitin ligase SMURF2 to the TGF-beta receptor complex. In addition, SMAD7 recruits the PPP1R15A-PP1 complex to TGFBR1, promoting dephosphorylation of the receptor. It positively regulates PDPK1 kinase activity by stimulating its dissociation from the 14-3-3 protein YWHAQ, a negative regulator.
The SMAD7 protein is nuclear at baseline and binds SMURF2. On binding, the complex moves to the cytoplasm and interacts with TGF-beta receptor type-1 (TGFBR1). This leads to degradation of both SMAD7 and TGFBR1. Expression of the SMAD7 gene is itself induced by TGFBR1, which places it in a negative feedback loop on receptor signalling. UniProt records localisation in both the nucleus and the cytoplasm. Several transcript variants encoding different isoforms have been described. Mouse and rat both have a Smad7 ortholog.
SMAD7 belongs to the dwarfin/SMAD family. Its previous names, such as MAD and mothers against decapentaplegic homolog 7 (Drosophila), reflect the founding Drosophila gene of the family. Variations in the SMAD7 gene are associated with susceptibility to colorectal cancer type 3 (CRCS3). Researchers studying SMAD7 often consider it alongside receptor-regulated and co-SMAD proteins such as SMAD1, SMAD5, Smad2/3 and Smad4, and the related inhibitory protein SMAD6.
SMAD7 antagonises TGF-beta and activin signalling at the receptor, making it a key node for studying negative regulation of this pathway.
SMAD7 recruits SMURF2 to TGFBR1, leading to degradation of the receptor and of SMAD7 itself.
SMAD7 recruits the PPP1R15A-PP1 complex to TGFBR1, promoting its dephosphorylation and offering a route to study receptor inactivation.
Variations in the SMAD7 gene are linked to susceptibility to colorectal cancer type 3 (CRCS3).
SMAD7 antagonises signalling by TGF-beta type 1 receptor superfamily members. It associates with receptors to block SMAD2 access, recruits SMURF2 to the receptor complex, and brings the PPP1R15A-PP1 complex to TGFBR1 to promote its dephosphorylation. It also promotes PDPK1 kinase activity.
SMAD7 is also known as MADH7 and MADH8. Earlier names include MAD and mothers against decapentaplegic homolog 7 (Drosophila). Several transcript variants encoding different isoforms have been reported, so check the datasheet of any product for its validated reactivity and isoform coverage.
Variations in the SMAD7 gene are a cause of susceptibility to colorectal cancer type 3 (CRCS3). Mouse and rat each have a Smad7 ortholog, so the protein can be studied in rodent models; check the datasheet of any product for its validated reactivity.
Other SMAD family members, including inhibitory, receptor-regulated and common-mediator proteins that act in TGF-beta superfamily signalling.
Gene and protein annotations from HGNC, NCBI Gene and UniProt O15105; product specifications from Assay Genie datasheets.